AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25732415 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroflexion View (RV)
Number of subjects: 850
Study 23899791 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention (2-hour informative session and non-supervised physical activity programme)
Number of subjects: 756
Study 23899791 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 756
Study 21937808 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic band ligation (ligation group)
Number of subjects: 105
Study 21937808 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy and perisoph‐agogastric devascularization (laparotomy group)
Number of subjects: 105
Study 21937808 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy, perisoph‐agogastric devascularization and endoscopic variceal ligation (combination group)
Number of subjects: 105
Study 19155351 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intramuscular electrical stimulation for hand opening (n = 13)
Number of subjects: 26
Study 19155351 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous electrical stimulation for sensory stimulation only (n = 13)
Number of subjects: 26
Study 17911040 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medications
Number of subjects: 0
Study 17911040 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated girls (Control)
Number of subjects: 0
Study 15019537 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (200 mg/day)
Number of subjects: 36
Study 15019537 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (500 mg/day)
Number of subjects: 36
Study 15019537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fenofibrate and Vitamin E
Number of subjects: 36
Study 12500879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implants
Number of subjects: 409
Study 12500879 — intervention group
Group type: COMPARATOR
Intervention: Natural teeth
Number of subjects: 409
Study 12500879 — intervention group
Group type: COMPARATOR
Intervention: Natural teeth and implants
Number of subjects: 409
Study 12500879 — intervention group
Group type: EXPERIMENTAL
Intervention: Periotest
Number of subjects: 409
Study 12500879 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in PTVs
Number of subjects: 409
Study 9141204 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms Engerix-B vaccine
Number of subjects: 52
Study 9141204 — intervention group
Group type: COMPARATOR
Intervention: 40 micrograms Engerix-B vaccine
Number of subjects: 52
Study 7536068 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon wool exposure
Number of subjects: 14
Study 3319012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g aztreonam
Number of subjects: 179
Study 3319012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 30796598 — intervention group
Group type: EXPERIMENTAL
Intervention: New peanut allergen treatment
Number of subjects: 0
Study 30796598 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30412221 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with TPF (docetaxel, cisplatin, 5-FU omitted in subsequent patients) followed by radiotherapy (69.6 Gy)
Number of subjects: 173
Study 30412221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to induction chemotherapy (IC) with TPF followed by radiotherapy (69.6 Gy)
Number of subjects: 173
Study 30412221 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (IC) with TPF followed by radiotherapy (69.6 Gy)
Number of subjects: 173
Study 27077348 — intervention group
Group type: EXPERIMENTAL
Intervention: Na‐reduction intervention
Number of subjects: 975
Study 27077348 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 975
Study 24215123 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete construal diaries
Number of subjects: 0
Study 24215123 — intervention group
Group type: COMPARATOR
Intervention: Mindful self-compassionate meditation programme
Number of subjects: 0
Study 24215123 — intervention group
Group type: COMPARATOR
Intervention: Abstract construal diaries
Number of subjects: 0
Study 22377815 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol LA (240 mg/day)
Number of subjects: 191
Study 22377815 — intervention group
Group type: COMPARATOR
Intervention: Topiramate alone (50-100 mg/day)
Number of subjects: 191
Study 19615827 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion meditation training
Number of subjects: 32
Study 19615827 — intervention group
Group type: COMPARATOR
Intervention: TSST administered prior to compassion meditation training
Number of subjects: 32
Study 18752682 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal replacement (HP)
Number of subjects: 100
Study 18752682 — intervention group
Group type: COMPARATOR
Intervention: Standard protein meal replacement (SP)
Number of subjects: 100
Study 16006194 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 fatty acid supplementation (1 g eicosapentaenoic acid (EPA) and 0.7 g docosahexaenoic acid (DHA) daily)
Number of subjects: 57
Study 16006194 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 57
Study 12061623 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial consistency (consistent)
Number of subjects: 130
Study 12061623 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial consistency (inconsistent)
Number of subjects: 130
Study 12061623 — intervention group
Group type: EXPERIMENTAL
Intervention: Witness confidence (high)
Number of subjects: 130
Study 12061623 — intervention group
Group type: EXPERIMENTAL
Intervention: Witness confidence (low)
Number of subjects: 130
Study 9859905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 34
Study 9859905 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (NCPAP)
Number of subjects: 34
Study 8725038 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg BCG therapy
Number of subjects: 111
Study 8725038 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg BCG therapy
Number of subjects: 111
Study 2094375 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymic extracts (TP1)
Number of subjects: 2
Study 2094375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 352142 — intervention group
Group type: EXPERIMENTAL
Intervention: Duck Embryo Vaccine (DEV), 4 doses
Number of subjects: 0
Study 352142 — intervention group
Group type: EXPERIMENTAL
Intervention: WI-38 Vaccine (WRV), 4 doses
Number of subjects: 0
Study 352142 — intervention group
Group type: EXPERIMENTAL
Intervention: WI-38 Vaccine (WRV), 2 doses
Number of subjects: 0
Study 352142 — intervention group
Group type: EXPERIMENTAL
Intervention: WI-38 Vaccine (WRV), 3 or 4 doses
Number of subjects: 0
Study 31789778 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthVoyager (VR experience)
Number of subjects: 41
Study 31789778 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (printed reports)
Number of subjects: 41
Study 31029515 — intervention group
Group type: COMPARATOR
Intervention: 10-10-PLAIN (non-adjuvanted formulation)
Number of subjects: 120
Study 31029515 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-10-AS01 (AS01-adjuvanted formulation with 10 µg of each antigen)
Number of subjects: 120
Study 31029515 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-3-AS01 (AS01-adjuvanted formulation with 10 µg of each NTHi antigen and 3.3 µg of Mcat antigen)
Number of subjects: 120
Study 31029515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28662170 — intervention group
Group type: EXPERIMENTAL
Intervention: healthMpowerment online intervention
Number of subjects: 465
Study 26488693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide 500 mg twice daily
Number of subjects: 386
Study 26488693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 23360885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 50 mg
Number of subjects: 60
Study 23360885 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Number of subjects: 60
Study 23360885 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 60
Study 21459987 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-GSH
Number of subjects: 160
Study 21459987 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 19124698 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking in the film trailer (42 seconds, character smoked for about 3 seconds)
Number of subjects: 1051
Study 19124698 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking film trailer (control)
Number of subjects: 1051
Study 17077229 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB‐2914 (50 mg single dose)
Number of subjects: 1549
Study 17077229 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (0.75 mg two doses taken 12 hours apart)
Number of subjects: 1549
Study 17077229 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB‐2914
Number of subjects: 1549
Study 17077229 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel
Number of subjects: 1549
Study 15039761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release d‐amphetamine (escalating 15‐30 or 30‐60 mg)
Number of subjects: 240
Study 15039761 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 240
Study 15039761 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2 or 4 mg)
Number of subjects: 240
Study 15039761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 11547367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented acetabular components
Number of subjects: 90
Study 11547367 — intervention group
Group type: COMPARATOR
Intervention: Cementless acetabular components
Number of subjects: 90
Study 11547367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 11547367 — intervention group
Group type: COMPARATOR
Intervention: Cementless components
Number of subjects: 90
Study 9097530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (100 micrograms/kg, two single doses, 3 months apart)
Number of subjects: 240
Study 9097530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 8242317 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (25 Gy in five fractions over 1 week)
Number of subjects: 1168
Study 8242317 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1168
Study 8242317 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation
Number of subjects: 1168
Study 2871216 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal tubular dysfunction assessment in stone formers
Number of subjects: 214
Study 30459468 — intervention group
Group type: COMPARATOR
Intervention: Sham deep breathing
Number of subjects: 13
Study 30459468 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEP
Number of subjects: 13
Study 30459468 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEP + OIS
Number of subjects: 13
Study 28715809 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drains (group 1; n = 108)
Number of subjects: 215
Study 28715809 — intervention group
Group type: COMPARATOR
Intervention: No suction drains (group 2; n = 107)
Number of subjects: 215
Study 26386381 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey based formulation of Nigella sativa seed oil (5 ml N. sativa oil orally daily) for 8 weeks
Number of subjects: 70
Study 26386381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23000726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol patches (1-2mg daily)
Number of subjects: 64
Study 23000726 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (4-5mg/kg daily)
Number of subjects: 64
Study 23000726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 22166100 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical framework for assessing uncertainty prior to patient recruitment
Number of subjects: 0
Study 22166100 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert panel opinions
Number of subjects: 0
Study 22166100 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision rule selected
Number of subjects: 0
Study 19087899 — intervention group
Group type: EXPERIMENTAL
Intervention: TSD and paroxetine treatment
Number of subjects: 16
Study 19087899 — intervention group
Group type: EXPERIMENTAL
Intervention: TSD and 2 weeks of placebo followed by paroxetine treatment
Number of subjects: 16
Study 19087899 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks of paroxetine treatment
Number of subjects: 16
Study 17070644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands‐Off Technique
Number of subjects: 30
Study 17070644 — intervention group
Group type: COMPARATOR
Intervention: Standard Hand Position
Number of subjects: 30
Study 17070644 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐Finger Fulcrum Technique
Number of subjects: 30
Study 17070644 — intervention group
Group type: EXPERIMENTAL
Intervention: Five‐Finger Fulcrum Technique
Number of subjects: 30
Study 15330779 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor air supply rate at 10 l/s/p and temperature at 24.5 degrees C
Number of subjects: 0
Study 15330779 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor air supply rate at 5 l/s/p and temperature at 22.5 degrees C
Number of subjects: 0
Study 15330779 — intervention group
Group type: COMPARATOR
Intervention: Outdoor air supply rate at 5 l/s/p and temperature at 24.5 degrees C
Number of subjects: 0
Study 15330779 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature reduction from 24.5 degrees C to 22.5 degrees C at 10 l/s/p
Number of subjects: 0
Study 11094581 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (900 mg per 24 h)
Number of subjects: 155
Study 11094581 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (4 g per 24 h)
Number of subjects: 155
Study 11094581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl; 50 ml per 24 h)
Number of subjects: 155
Study 8833058 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (MTX 17.5 mg/week, sulfasalazine 500 mg bid, hydroxychloroquine 200 mg bid)
Number of subjects: 28
Study 8833058 — intervention group
Group type: COMPARATOR
Intervention: Combination of hydroxychloroquine and sulfasalazine
Number of subjects: 28
Study 8833058 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 28
Study 1430130 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin releasing hormone agonist (GnRHa) in the midluteal phase coupled with follicular phase administration of human menopausal gonadotrophin
Number of subjects: 28
Study 1430130 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 28
Study 3908501 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol 5 mg
Number of subjects: 35
Study 3908501 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol 20 mg
Number of subjects: 35
Study 3908501 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study 2424123 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G
Number of subjects: 113
Study 2424123 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 113
Study 2424123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 31751183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg bid)
Number of subjects: 87
Study 31751183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 30047286 — intervention group
Group type: EXPERIMENTAL
Intervention: Coencapsulated TDF/FTC with the Proteus ingestible sensor
Number of subjects: 24
Study 30047286 — intervention group
Group type: COMPARATOR
Intervention: Unencapsulated TDF/FTC
Number of subjects: 24
Study 28741804 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein group (1.2 g/kg per day protein diet + 25% additional whey protein supplement)
Number of subjects: 36
Study 28741804 — intervention group
Group type: COMPARATOR
Intervention: Control group (1.2 g/kg per day protein diet without additional whey protein supplementation)
Number of subjects: 36
Study 26446265 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 200
Study 23130909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (400 mg) plus folic acid (600 µg)
Number of subjects: 271
Study 23130909 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (ferrous sulfate with folic acid)
Number of subjects: 271
Study 23130909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intravenous iron and oral iron
Number of subjects: 271
Study 21508850 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0
Study 21508850 — intervention group
Group type: COMPARATOR
Intervention: Other antipsychotics
Number of subjects: 0
Study 21508850 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 18311683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active high-frequency rTMS over the left cortex
Number of subjects: 45
Study 18311683 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 45
Study 17133559 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg)
Number of subjects: 106
Study 17133559 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg) with methotrexate
Number of subjects: 106
Study 14535876 — intervention group
Group type: COMPARATOR
Intervention: Empirical treatment with ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Number of subjects: 242
Study 14535876 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial sensitivity testing-based treatment with ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Number of subjects: 242
Study 14535876 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole, 20 mg b.d., clarithromycin, 500 mg b.d., and amoxicillin, 1 g b.d.
Number of subjects: 242
Study 14535876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Number of subjects: 242
Study 10746516 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg magnesium + 50 mg vitamin B6
Number of subjects: 44
Study 10746516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9545899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine irrigation using a powered oral irrigator (Water Pik)
Number of subjects: 0
Study 9545899 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate rinsing once daily
Number of subjects: 0
Study 9545899 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 0.06% chlorhexidine irrigation and 0.12% chlorhexidine rinsing
Number of subjects: 0
Study 1408551 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned bottle group (one bottle daily between the second and sixth weeks postpartum)
Number of subjects: 121
Study 1408551 — intervention group
Group type: COMPARATOR
Intervention: Total breast-feeding group (avoiding bottles during the same period)
Number of subjects: 121
Study 1408551 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned bottle group
Number of subjects: 121
Study 1408551 — intervention group
Group type: COMPARATOR
Intervention: Total breast-feeding group
Number of subjects: 121
Study 3930197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroderm TTS 10
Number of subjects: 8
Study 3930197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitradisc 10
Number of subjects: 8
Study 3930197 — intervention group
Group type: EXPERIMENTAL
Intervention: Deponit 10
Number of subjects: 8
Study 3930197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitro‐Pflaster‐ratiopharm 10
Number of subjects: 8
Study 30528222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60mg once daily orally
Number of subjects: 119
Study 30528222 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone 12mg/m2 every 3 weeks plus prednisone 5mg twice daily orally
Number of subjects: 119
Study 28903131 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive MGMT expression
Number of subjects: 445
Study 28903131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-based adjuvant chemotherapy in MGMT-positive patients
Number of subjects: 445
Study 26700279 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Multistep Medication Review (3MR)
Number of subjects: 160
Study 26700279 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care by pharmacist and general practitioner)
Number of subjects: 160
Study 24034941 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual pictogram (SAP‐c version)
Number of subjects: 12
Study 21346608 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 21346608 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 0
Study 21346608 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 21346608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19698734 — intervention group
Group type: EXPERIMENTAL
Intervention: GVG (1 g/day increased to 5 g/day)
Number of subjects: 17
Study 19698734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 19698734 — intervention group
Group type: EXPERIMENTAL
Intervention: GVG
Number of subjects: 17
Study 17645444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 2573
Study 15025222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (20 mg) b.i.d. for 3 months plus scaling and root planing (SRP)
Number of subjects: 30
Study 15025222 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules b.i.d. for 3 months plus scaling and root planing (SRP)
Number of subjects: 30
Study 11597949 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E at 300 mg/d during dinner (group B)
Number of subjects: 20